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We examined the neutralizing/enhancing activity in sera collected at an early and a later time point postinfection from 13
HIV-positive nonprogressors, 13 moderate progressors, and 13 rapid progressors to determine the relationship between
neutralizing/enhancing activity and disease progression. Early sera from each group reduced virus replication at low dilutions
(1021 to 1022) when compared with negative sera. The reduction was statistically significant for moderate and rapid
progressors at 1021 dilution (P 5 0.02 and P 5 0.02 respectively) but not for nonprogressors (P 5 0.16). Late sera from
nonprogressors and moderate progressors reduced virus replication at low dilution but late sera from rapid progressors lost
neutralizing activity. These data suggest that an association exists between neutralizing activity in sera and nonprogression
or slower progression to disease and that loss of neutralizing activity is associated with disease progression. At higher
dilutions (1023 to 1026), both early and late sera from each group increased virus replication over negative sera. The levels
and frequency of enhancement were higher for sera from a subgroup of nonprogressors than a subgroup of rapid
progressors who exhibited enhancement. This suggests that enhancement is not associated with disease progression. The
neutralizing/enhancing activity observed in sera of these three groups of subjects suggest that enhancement levels may
reflect the overall level of antibody response to HIV. The replication patterns observed for early and late sera from individuals
in the different groups reflect changes in antibody activity that appear to be associated with protection or disease
progression. © 2000 Academic PressINTRODUCTION
Protective immunity to HIV-1 is likely to involve a
strong cellular, particularly cytotoxic T-lymphocyte (CTL)
immune response (Koup et al., 1994) as well as an
effective neutralizing antibody response (Zolla-Pazner et
al., 1997). It has been reported that individuals who have
been infected with HIV for prolonged periods (10 years)
and who maintain intact immune systems and no symp-
toms of disease (long-term nonprogressors; LTNP), ex-
hibit strong CTL responses but low to undetectable titers
of neutralizing antibody against a panel of HIV-1 primary
isolates (Harrer et al., 1996). This finding led to the
conclusion by the authors that long-term nonprogressing
HIV-1 infection may not require the presence of broadly
cross-reactive neutralizing antibodies and raised doubts
of the protective role of neutralizing antibodies in dis-
ease progression. In contrast, other studies have shown
sustained HIV-1-specific antibody response to HIV-1 pri-
mary isolates in HIV-positive nonprogressors (Cao et al.,
1995) and minimal or no such responses in individuals
who progress rapidly to AIDS (rapid progressors, RP;
Zhang et al., 1997), suggesting that the antibody re-
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52sponse is in fact associated with protection from dis-
ease. Cecilia et al. (1999) found that long-term nonpro-
gressors and rapid progressors had similar levels of
neutralizing antibodies at an early time point postinfec-
tion against HIV-1 primary isolates, but that at a later time
point, the LTNP had significantly higher titers of neutral-
izing antibodies in serum compared to the rapid progres-
sors. Carotenuto et al. (1998) reported that neutralizing
antibodies to primary HIV-1 isolates were preferentially
found in HIV-1-infected LTNP who had relatively pre-
served T-cell function and CD41 T cell numbers. More
recent reports show that neutralizing antibodies against
HIV can prevent infection in primates and accelerate
removal of HIV from the blood (Shibata et al., 1999;
Igarashi et al., 1999).
In contrast to neutralizing antibodies, which are consid-
ered important in control of virus replication, antibodies that
enhance HIV replication in vitro by either Fc gamma recep-
tor-mediated endocytosis (FcgR-ADE) of primary isolates in
PBMCs (Homsy et al., 1988, 1990) or complement receptor-
mediated endocytosis (C9-ADE) of T-cell line-adapted virus
(Robinson et al., 1988; Dolin et al., 1991; Montefiori et al.,
1992) have been identified in sera from HIV-1-infected indi-
viduals and from many gp120-vaccinated volunteers. En-
hancing antibodies are associated with increased viremias,
increased disease severity, and vaccine failures in other
virus systems (Barrett and Gould, 1986; Chin et al., 1969;
Fulginiti et al., 1969; Halstead, 1988; Halstead and O’Rourke,
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53HIV NEUTRALIZATION/ENHANCEMENT AND DISEASE PROGRESSION1977; Peiris and Porterfield, 1979; Rauh and Schmidt, 1965;
Vennema et al., 1990) and are of concern with regard to the
afety and efficacy of HIV-1 vaccines (Bolognesi, 1989;
urke, 1992; Mascola et al., 1993). However, the role of
nhancing antibodies in disease development and pro-
ression in HIV-1 infection remains undetermined.
C9-ADE has been shown to be unimportant in clinical
isease with HIV and SIV. No correlation between titers
f C9-ADE and disease progression was found in HIV-
ositive individuals (Montefiori et al., 1991) or in SIV-
nfected rhesus macaques (Montefiori et al., 1990). Fur-
her, Montefiori et al. (1996) reported that C9-ADE was
qually prevalent in sera from LTNP and non-LTNP and
hat long-term nonprogression was not associated with
bsence of C9-ADE. We believed that FcgR-ADE of HIV-1
infection in macrophages would be more relevant to
clinical disease because this type of enhancement is
characteristic of diseases such as dengue and feline
infectious peritonitis for which ADE has been best dem-
onstrated to occur (Halstead, 1988; Halstead and
O’Rourke, 1977; Vennema et al., 1990) and because mac-
ophages are important target cells for HIV-1 infection
nd replication in vivo. Most HIV-1 variants that are
solated from patients are capable of infecting macro-
hages (Valentin et al., 1994) and the attachment of
ntibody-coated virus from either serum or blood to Fcg
receptors on susceptible cells, such as macrophages, is
believed to be the earliest event in HIV infection (Lehner
et al., 1991).
Kostrikis et al. (1996) have reported that a significant
proportion (28%) of a large number of combinations of
sera and HIV-1 primary isolates (from all genetic sub-
types) caused serum-dependent infectivity enhancement
FIG. 1. Neutralization/enhancement of HIV-1BaL replication by early s
eplication [determined by p24 antigen (pg/ml) in culture fluids collec
IV-1-negative individuals. The data represent the average of at least twrather than neutralization and that certain virus isolates rwere more sensitive to serum enhancement. We exam-
ined neutralization/enhancement of a R5 tropic strain of
HIV-1 in monocyte-derived macrophage (MDM) cultures
by sera of HIV-1-infected nonprogressors (stable), and
moderate and rapid progressors from the Multicenter
AIDS Cohort Study (MACS) to determine the relationship
between neutralizing/enhancing activity in sera and dis-
ease progression in HIV-1-infected individuals.
RESULTS
Neutralization/enhancement of HIV-1 by sera of
stable, moderate, and rapid progressors compared
to negative sera: early and late sera
When the effect of sera was examined by group, early
sera from each group neutralized or reduced HIV repli-
cation at low dilutions (1021 to 1022) when compared with
era from HIV-1-negative individuals (Fig. 1). The reduc-
ion was statistically significant for moderate and rapid
era at 1021 dilution (P 5 0.02 for both groups) but was
ot significant for stable sera (P 5 0.16). The reductions
ere not statistically significant at 1022 dilution. At higher
ilutions (1023 to 1026), early sera from each group in-
creased virus replication over the negative sera, al-
though this was not statistically significant. At the high-
est dilution (1026), there was a noticeable drop in the
nhancing activity in sera from the rapid progressors.
Late sera from stable individuals and moderate pro-
ressors reduced virus replication compared with HIV-1
egative sera at 1021 dilution, but late sera from rapid
rogressors supported virus replication similar to nega-
ive sera (Fig. 2). At 1022 dilution, only late sera from
oderate progressors reduced virus replication. These
m nonprogressors (stable) and moderate and rapid progressors. Virus
days p.i.] is compared to replication of virus treated with sera from
pendent infections (4 data points) for each of 13 sera from each group.era fro
ted 2–4eductions at both dilutions did not achieve statistical
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54 JOLLY AND WEISSsignificance (P . 0.05). At 1022 dilution, sera from stable
individuals supported virus replication similar to negative
sera, and sera from rapid progressors increased virus
replication above that with negative sera. At 1023 to 1024
dilutions, late sera from all the groups enhanced virus
replication, and at 1025 and 1026 dilutions late sera from
he stable and rapid groups enhanced replication. The
nhancing effect was greater at all dilutions with sera
rom the stable than from the rapid group. None of these
ncreases achieved statistical significance for all groups.
FIG. 2. Neutralization/enhancement of HIV-1BaL replication by late s
eplication [determined by p24 antigen (pg/ml) in culture fluids collec
IV-1-negative individuals. The data represent the average of at least tw
FIG. 3. Level of enhancement of HIV-1BaL by early sera of a subgro
eplication [determined by p24 antigen (pg/ml) in culture fluids collec
IV-1-negative individuals. The data represent two independent infections (4evel of enhancement of HIV-1 by sera of stable,
oderate, and rapid progressors on a subgroup
f subjects exhibiting enhancement
Figure 3 shows percent enhancement of early sera for
ach group of subjects by dilution. There was a statisti-
ally significant enhancement at almost all serum dilu-
ions (1023 to 1026) in the stable group (P , 0.05). A
ignificant enhancement was also observed in the mod-
rate group but only at 1025 and 1026 dilutions (P 5 0.05
m nonprogressors (stable) and moderate and rapid progressors. Virus
days p.i.] is compared to replication of virus treated with sera from
pendent infections (4 data points) for each of 13 sera from each group.
table, moderate and rapid progressors exhibiting enhancement. Virus
days p.i.] is compared to replication of virus treated with sera fromera fro
ted 2–4up of s
ted 2–4data points) for seven sera from each group.
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55HIV NEUTRALIZATION/ENHANCEMENT AND DISEASE PROGRESSIONand P 5 0.03, respectively). Some enhancement was
also observed at 1023 (P 5 0.03) and 1025 (P 5 0.05)
dilutions for the rapid progressor group.
Figure 4 shows a similar pattern of significant en-
hancement at almost all dilutions of the late sera from
the stable group. However, no significant enhancement
was observed in the late sera for the moderate group
and enhancement was observed only at 1024 dilution
P 5 0.05) for the rapid group.
imilarity in the effect of early and late sera from an
ndividual in each of the three groups of patients on
IV-1 replication
When the samples were decoded, we observed that
arly and late sera from several of the HIV-1-positive
ndividuals showed similarity and differences in neutral-
zing/enhancing patterns that reflect the group data and
ppear to be associated with protection or disease pro-
ression. The patterns of a representative subject from
ach group are presented in Figs. 5A–5C. Figure 5A
hows the replication patterns of early and late sera from
stable individual. At the lowest serum dilution (1021),
early sera from this individual did not neutralize virus
whereas the late serum neutralized virus. The neutraliz-
ing activity by late serum was lost with one higher 10-fold
dilution of the serum, and both the early and late sera
enhanced virus growth similarly at all higher dilutions.
The neutralization/enhancement patterns by early and
late sera from a moderate progressor are presented in
Fig. 5B. Both early and late sera neutralized virus at the
FIG. 4. Level of enhancement of HIV-1BaL by late sera of a subgrou
replication [determined by p4 antigen (pg/ml) in culture fluids collect
HIV-1-negative individuals. The data represent two independent infecti
each of the moderate and rapid progressor groups.lowest dilution and enhanced replication at all otherdilutions (Fig. 5B). The neutralization/enhancement pat-
terns obtained with early and late sera from a rapid
progressor are shown in Fig. 5C. These patterns are
interesting in that the ability to reduce virus replication
shown by the early serum at the lowest dilution was lost
in the late serum of this rapid progressor. Rather, the late
serum enhanced virus replication at all dilutions. Nota-
bly, after 1025 dilution the enhancing activity of both the
early and late sera from this individual dropped. This
drop is reflective of the drop shown for the rapid pro-
gressor group at 1026 dilution shown in Fig. 1.
DISCUSSION
Early sera from each of the three groups of HIV-1-
ositive patients examined in this study had neutralizing
ctivity at low dilutions and enhancing activity at higher
ilutions. Late sera from nonprogressors and moderate
rogressors still neutralized or reduced virus replication
t low dilution similar to their early sera, but for rapid
rogressors low dilutions of late sera (in contrast to their
arly sera) did not neutralize virus. This may indicate an
ssociation between the presence of neutralizing anti-
ody to HIV-1 and nonprogression or slower progression
o disease. The data also suggest that loss of neutraliz-
ng activity is associated with disease progression since
he sera of rapid progressors lost the capability of neu-
ralizing virus that their early sera showed. This finding is
n agreement with previous reports (Zhang et al., 1997;
ao et al., 1995; Pilgrim et al., 1997; Carotenuto et al.,
1998) that the neutralizing antibody response is higher in
able, moderate, and rapid progressors exhibiting enhancement. Virus
days p.i.] is compared to replication of virus treated with sera from
data points) for eight sera from the stable group and seven sera fromp of st
ed 2–4
ons (4asymptomatic patients with long-standing infection than
56 JOLLY AND WEISSin patients who progressed to AIDS. Cao et al. (1995)
showed that there was sustained HIV-1-specific antibody
responses in HIV-1- positive nonprogressors, and other
researchers have shown minimal or no neutralizing an-
tibody response in rapid progressors (Robert-Guroff et
al., 1986; Hogervorst et al., 1995; Zhang et al., 1997;
Carotenuto et al., 1998). Carotenuto et al. (1998) found
that neutralizing antibody titers increased in LTNP but
FIG. 5. Replication of HIV-1BaL treated with early and late sera from
a stable subject (A), a moderate progressor (B), and a rapid progressor
(C). The data represent two independent infections (4 data points) for
early and late sera for each subject.were sporadically positive and in low range in rapidprogressors. Remarkably, our data are quite similar to
that of Cecilia et al. (1999), who showed comparable
levels of neutralizing antibodies in early sera of LTNP
and RP from a similar sample of MACS patients. They
also showed significantly higher neutralizing antibody
titers in the late sera of LTNP compared to RP. This is
similar to the maintenance of neutralizing activity that we
observed in the late sera from nonprogressors and a
decrease in neutralizing activity in rapid progressors.
The similarity in the data obtained in the two studies is
even more remarkable considering the differences in the
cell types and HIV isolates that were used.
This study also sheds light on the question of whether
low levels or absence of neutralizing antibody in sera of
patients with some degree of disease progression reflect
the inability to mount or sustain such humoral response
or results from a progressive loss of specific antibodies
that parallels the worsening clinical and immunological
conditions that occur in these individuals. It shows that
the majority of HIV positive subjects mount a neutralizing
antibody response to the infection but that rapid progres-
sors seem to be unable to sustain such a response in the
way that moderate progressors and nonprogressors do.
It is interesting that even though the neutralizing ac-
tivity in sera of stable and moderate progressors seems
to be associated with slower progression or nonprogres-
sion to disease, strong enhancing activity was observed
in the sera of nonprogressors and to a lesser extent of
moderate progressors at higher dilutions. Therefore,
both neutralizing and enhancing antibodies occur in
these sera simultaneously. If neutralizing antibody is
present, enhancement is observed only at high dilutions
of sera, whereas, if only enhancing antibody is present,
enhancement is observed without or at low serum dilu-
tion. Kostrikis et al. (1996) pointed out that enhancing
antibodies may partially counter the effects of neutraliz-
ing antibodies leading to a reduction in the extent of
neutralization that might otherwise occur. The low neu-
tralizing titers of the sera in this study may be a result of
the counter effects of enhancing antibodies. Kostrikis et
al. (1996) also noted that sera selected to contain high
titers of antibodies reactive with gp120 monomers were
more likely to cause infectivity enhancement than were
unselected sera probably because sera high in anti-
gp120 titers may also have relatively abundant antibod-
ies to the gp41 epitope associated with receptor-medi-
ated enhancement (Eaton et al., 1994). The higher level of
neutralizing as well as enhancing activity observed with
late sera from stable individuals compared to rapid pro-
gressors may indicate that stable individuals produce
and sustain an overall more vigorous antibody response
to HIV-1 than do rapid progressors. The drop in enhanc-
ing activity of early sera from rapid progressors at high
dilution (1026) may indicate an overall lower level of
anti-HIV antibodies in their sera compared with the lev-
els in sera of stable individuals.Examination of the data from subgroups of subjects
C
P
57HIV NEUTRALIZATION/ENHANCEMENT AND DISEASE PROGRESSIONwhose sera exhibited enhancement revealed significant
differences between the sera in each group and seroneg-
ative sera. However, higher levels of enhancement were
observed in the stable group than the rapid progressor
group. The higher levels of enhancing activity in stable sera
(and comparable levels in moderate sera) in relation to
rapid sera suggest that enhancing activity may not be
associated with disease progression. Rather, enhancement
levels may indicate only the overall level of the antibody
response in the subjects. Further, the fact that both nonpro-
gressors and rapid progressors had enhancing activity in
sera suggests that the net effect of neutralizing/enhancing
activity may be the important factor in disease progression
rather than the presence of enhancing activity. However,
because we examined sera from only two time points, early
and late postinfection, we have not been able to determine
the levels of neutralizing/enhancing activity in sera at se-
quential time points postinfection and do not know how and
when these levels change. A longitudinal study of sequen-
tial serum samples from a group of LTNP and RP would
clarify the time of development and levels of enhancing
antibodies throughout infection and so give better insight
into any role these antibodies may play in disease progres-
sion.
Examination of replication patterns of early and late
sera from individuals from the different groups showed
either development of neutralizing activity in late sera
(stable subject) or loss of neutralizing activity in late sera
(rapid progressor) compared to early sera. The similar
replication patterns observed for the early and late sera
of the moderate progressor showed that at low dilution
the late serum maintained the neutralizing activity ob-
served in the early serum. These observations were
remarkable in that they seem to reflect the changes that
appear to be associated with protection or disease pro-
gression. The data also indicate that once established,
antibody level and activity may not change much
throughout infection for long-term survivors.
MATERIALS AND METHODS
Serum samples
Serum samples from 45 HIV-1-infected individu-
als—15 nonprogressors (stable), 15 moderate progres-
sors, and 15 rapid progressors, who were classified on
the basis of the rate of depletion of CD41 T cells and
absence or presence of clinical symptoms—were pro-
vided by the MACS group (Gange et al., 1997). Stable
individuals were selected from HIV-1-seropositive men
for whom longitudinal data had been collected, who had
not used zidovudine, and who had no decline in CD41 T
lymphocytes over time (Munoz et al., 1995). Moderate
progressors were subjects with long-term follow-up, no
use of zidovudine, and a decline of 10 CD41 T lympho-
cytes per semester. Finally, rapid progressors were se-
lected from a group of subjects with loss of 53 CD41 Tcells per semester. For each subject, serum samples
from two visits were provided, one relatively early (2.5
years postenrollment) and the other later (4–10 years
postenrollment) when the three groups showed different
rates of disease progression and had very different pat-
terns of CD41 T cell decline (Table 1). Because of short-
age of serum samples, 13 of 15 sera from each of the
stable, moderate, and rapid progressor groups, and 15
seronegative sera were tested against HIV-1BaL. One se-
rum sample from each of 15 seronegative individuals
TABLE 1
CD41 T-Cell Number at Collection and Time Interval Between
ollection of Early and Late Sera for Stable and Moderate and Rapid
rogressor Groups
Group and
patient number
CD41 T cells/mm3
Time interval between
2 samples (years)At early visita At late visit
Stable
1 648 584 2.8
2 316 734 4.1
3 470 769 3
4 651 988 3.2
5 656 602 3.5
6 696 624 2.3
7 621 900 4.2
8 1005 952 2.5
9 973 1250 3
10 649 911 2.3
11 770 930 7.5
12 1299 941 4
13 882 1133 4.2
Moderate
1 407 235 2.5
2 645 454 3.9
3 685 488 3.4
4 685 300 2.8
5 518 491 2.1
6 778 483 2.3
7 871 599 4.3
8 906 599 2.4
9 756 605 1.8
10 489 371 2.2
11 586 258 7.3
12 1188 526 4
13 944 640 4.6
Rapid
1 393 8 3.5
2 670 12 4.2
3 576 12 2.5
4 343 27 3
5 689 6 3.4
6 666 100 1.8
7 605 38 4.8
8 594 170 3.1
9 571 19 3
10 226 70 2.1
11 777 125 7.3
12 903 9 3.7
13 788 81 4.2
a Early, most sera collected 2.5 years postenrollment.was also provided as negative controls. The samples
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58 JOLLY AND WEISSwere provided coded and tested blind for neutralization
or enhancement of HIV-1BaL in MDM cultures.
Preparation of monocyte-derived macrophages
Primary macrophages were prepared by culturing
freshly isolated peripheral blood mononuclear cells
(PBMC) in macrophage differentiation media [DMEM
plus 10% human AB serum (Biowhittaker, Walkersville,
MA) gentamicin (2 mg/ml), 2 mM glutamine, and 5 U/ml of
macrophage colony stimulating factor (M-CSF)]. Cells
were seeded in eight-well chamber slides (LabTek, Na-
perville, IL) using 0.5 ml of cell suspension per well.
Nonadherent cells were removed by vigorous pipetting.
Complete monolayers containing 4 3 105 cells/well were
btained in 6 days. Greater than 96% of adherent cells
repared this way were identified as monocyte-derived
acrophages by flow cytometry. PBMCs used to prepare
acrophages in all of these experiments were obtained
rom three donors to minimize variation of virus replica-
ion in host cells from different donors.
reparation of HIV-1BaL stock
Preparation of a stock of HIV-1BaL in primary macro-
hages was previously reported (Jolly, 1997). Briefly, HIV-
BaL supernatant fluid (1 3 104.6 TCID50/ml) obtained
rom the NIH AIDS Research and Reference Reagent
rogram was used to inoculate fresh cultures of macro-
hages grown on 75-ml tissue culture flasks. The cul-
ures were washed 24 h later and incubated with fresh
edia. Supernatant fluids were harvested at 7 and 14
ays p.i., clarified by centrifugation, titrated, and used as
tock virus for these studies. The stock contained 5 3
05 TCID50/ml.
Neutralization-enhancement assay
Sera were heat inactivated (56°C/30 min), serially di-
luted 10-fold (1021 to 1026), and incubated with HIV-1BaL
m.o.i. 5 0.025) for 30 min at 37°C on a shaking water
ath. The virus-serum mixtures were inoculated in dupli-
ate into MDM cultures and the cultures incubated over-
ight at 37°C in a 5% CO2 incubator. The inocula were
emoved and the cells washed, replenished with fresh
edia, and incubated for #10 days at 37°C. Culture
luids (200 ml) were collected immediately after washing
Day 0), and on Days 2, 4, 6, and 8 p.i. and tested for p24
ntigen using the Coulter assay (Coulter, Miami, FL).
ach serum sample was tested at least twice.
tatistical analysis
Descriptive statistics such as mean, median, and stan-
ard deviation were calculated for p24 antigen in each
roup of HIV-infected subjects (stable, moderate, rapid
rogressors) by dilution. The mean value of p24 antigen
y dilution was calculated from the seronegative sam-
les. The percent change (increase or decrease) in p24ntigen of each serum in each of the three groups from
he mean of the seronegative samples was calculated.
he mean percent change and standard errors were
lotted for each group of patients by dilution. The Wil-
oxon signed-ranks test was used to determine whether
he percent change was significantly different from zero.
his analysis was done separately for early and late
era.
Analysis was performed on a subgroup of patients
rom the stable, moderate, and rapid groups who exhib-
ted enhancement. Similar to the analysis described
bove, the percent change increase in p24 antigen of
ach serum in each of the three groups from the mean of
he seronegative samples was calculated. The mean
ercent change and standard errors were plotted for
ach group of patients by dilution. The Wilcoxon signed-
anks test was used to determine whether the percent
hange was significantly different from zero. This analy-
is was done separately for early and late sera.
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